Subscribe
Interview with the Innovators
Supported byAsk the Experts

Closely Monitoring of Regorafenib-Related Side Effects: When and Why

Ask the Experts
Videos
Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ
Daniel Ahn, DO, MS
Assistant Professor of Medicine
Mayo Clinic, AZ
Dr. Bekaii-Saab and Dr. Ahn offer the rationale for a practical monitoring schedule for patients treated with Regorafenib.

Related Items

Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Deciding Which Patients Are Best Suited for Various First-Line Pancreatic Cancer Treatment Options
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Considerations for Selecting a First-Line Pancreatic Cancer Treatment
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
How the Cost of Cancer Treatments May Affect Treatment Decisions for Patients
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Best Practices for Treating Adverse Events Associated With Pancreatic Cancer Therapies
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Key Side Effects That May Occur With First-Line Treatments for Patients With Pancreatic Cancer
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
The Importance of Median Progression-Free Survival in Oncology Clinical Trials
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Median Overall Survival of First-Line Treatments for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Evaluation of Patients for Pancreatic Cancer
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Videos
Interview with the Innovators
Practical Strategies for Reduced Risk of Regorafenib-Related Side Effects
By Tanios S. Bekaii-Saab, MD; Daniel Ahn, DO, MS
Videos
Ask the Experts

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?